We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Circulating Tumor DNA Test Clinically Validated

By LabMedica International staff writers
Posted on 23 May 2022
Print article
Image: Overview of the LiquidHALLMARK assay workflow (Photo courtesy of Lucence Diagnostics)
Image: Overview of the LiquidHALLMARK assay workflow (Photo courtesy of Lucence Diagnostics)

Next-generation sequencing of circulating tumor DNA presents a promising approach to cancer diagnostics, complementing conventional tissue-based diagnostic testing by enabling minimally invasive serial testing and broad genomic coverage through a simple blood draw to maximize therapeutic benefit to patients.

The diagnosis and sub-classification of cancers, fundamental to any cancer treatment algorithm, has historically been achieved through the study of the primary tumor tissue. The availability of high-quality diagnostic material suitable for high-end genomic technologies, including multiplexed tissue-based genotyping, is often limiting and associated with high risks and costs.

Scientists from Lucence Diagnostics Pte Ltd (Singapore, Singapore) collected 1,592 consecutive clinical samples included in the observational analyses were received as routine clinical samples and underwent standard processing and reporting at a CAP- and CLIA-accredited laboratory. Tubes of whole blood were collected for each patient in Streck Cell-Free DNA BCT (Streck, La Vista, NE, USA), shipped to Lucence Diagnostics at ambient temperature, and processed within 6–48 hours of sample collection.

The team used the Lucence Diagnostics’ LiquidHALLMARK which is an amplicon-based next-generation sequencing assay developed for the genomic profiling of plasma-derived cell-free DNA (cfDNA). The comprehensive 80-gene panel profiles point mutations, insertions/deletions, copy number alterations, and gene fusions, and further detects oncogenic viruses (Epstein-Barr virus (EBV) and hepatitis B virus (HBV)) and microsatellite instability (MSI).

The investigators reported analytical validation using reference genetic materials demonstrated a sensitivity of 99.4% for point mutations and 95.8% for insertions/deletions at 0.1% variant allele frequency (VAF), and a sensitivity of 91.7% for gene fusions at 0.5% VAF. In non-cancer samples, a high specificity (≥99.9999% per-base) was observed.

The limit of detection for copy number alterations, EBV, HBV, and MSI were also empirically determined. Orthogonal comparison of epidermal growth factor receptor (EGFR) variant calls made by LiquidHALLMARK and a reference allele-specific polymerase chain reaction (AS-PCR) method for 355 lung cancer specimens revealed an overall concordance of 93.8%, while external validation with cobas EGFR Mutation Test v2 (Roche, Basel, Switzerland) for 50 lung cancer specimens demonstrated an overall concordance of 84.0%, with a 100% concordance rate for EGFR variants above 0.4% VAF.

Clinical application of LiquidHALLMARK in 1,592 consecutive patients demonstrated a high detection rate (74.8% circulating tumor DNA (ctDNA)-positive in cancer samples) and broad actionability (50.0% of cancer samples harboring alterations with biological evidence for actionability). Among ctDNA-positive lung cancers, 72.5% harbored at least one biomarker with a guideline-approved drug indication.

The authors concluded that their results established the high sensitivity, specificity, accuracy, and precision of the LiquidHALLMARK assay and supports its clinical application for blood-based genomic testing. The study was published on April 29, 2022 in the journal PLOS ONE.

Related Links:
Lucence Diagnostics Pte Ltd 
Streck
Roche 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Saliva Collection Kit
SpeciMAX Stabilized Saliva Collection Kit
New
Medical Washer-Disinfector
BLUNIX 60
New
ELISA & CLIA Analyzer
Autoplex Gen2

Print article

Channels

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.